Shamnad Basheer

TL;DR: A global treaty is proposed to overcome the problems of substandard and falsified medicines and safeguard the quality of genuine medicine and criminalise falsified ones.

TL;DR: The Patents (Amendment) Act 2005 was the final step towards achieving complete TRIPS compliance in India as mentioned in this paper, and the 2005 Act attempts to balance out competing interests of a variety of stakeholders, including domestic generic medicine producers, the domestic research and development community, foreign multinational pharmaceutical companies, civil society groups concerned with access to medicines and (last but certainly not least), intellectual property lawyers.

TL;DR: In this paper, the authors argue that although the Madras High Court was correct in concluding that section 3(d) is constitutional, the court's reasoning leaves much to be desired.

TL;DR: In this article, the authors argue that if the role of the patent regime is one of fostering higher amounts of investment in the R&D process, it is better served by a direct investment protection regime, where the protection does not depend upon whether or not the underlying idea behind the drug is new and innovative, two central tenets of patent law.

TL;DR: In this paper, the authors argue that the Indian Patent Office has had an interesting history of taking itself to be a policy guardian of sorts and demonstrating a rather conservative approach to the issue of patentability.